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ABSTRACT: Resveratrol (3,5,4-trihydroxy-trans-
stilbene) is natural phenol and phytoalexin, 
extracted from red grapes, berries and cacao beans 
and found also in significant concentration in red 
wine. This active compound exhibited potent 
pleiotropic, antineoplastic activity without 
documented toxicity to normal cells. In addition, 
numerous studies reported that resveratrol, as most 
researched stilbene, possess numerous health-
benefit properties, such as cardioprotective, 
antidiabetic, neuroprotective and chemopreventive.  
Regretfully, clinical realization of resveratrol is 
restricted due to its poor aqueous solubility (0.05 
mg/ml), degradation at physiological pH associated 
with extremely low systemic bioavailability. An 
intriguing strategy to overcome these limitations is 
formulation of resveratrol-loaded nanoparticles 
such as nanoemulsions, liposomes and solid-lipid 






Resveratrol is biologically active 
polyphenol, isolated from skin of berries, grapes, 
cacao and peanuts, produced in order to protect the 
plant of inflammation, UV irradiation and fungal 
infection [1]. Resveratrol is identified as (3,5,4′-
trihydroxy-trans-stilbene), classified as natural 
polyphenol consisting of two phenolic rings 
attached by methylene bridge presented on Figure 
1. The presence of double bond is responsible for 
cis and trans isomerism of resveratrol. Many 
studies confirmed that trans isomer of resveratrol is 
more stable and biologically active isomer due to 
its non-planar conformation [2] [3] [4]. 
 
 
Figure 1. Structure of trans-resveratrol 
 
 Resveratrol was first isolated in 1939 by 
M.Takaoka from the rhizome of 
VeratrumGrandiflorum and is called resveratrol 
because it is resorcinol derivative from this species 
[5]. However, the interest in resveratrol has 
extensively increased after,, French paradox‖ in 
1992 based on epidemiological data collected from 
French volunteers from 30-70 years [6]. Results 
revealed lower mortality rate from cardiovascular 
diseases in French people with moderate wine 
intake despite the high consumption of high 
saturated fat [6]. Many in vitro studies proved that 
cardioprotective effect of resveratrol is associated 
with inhibition of LDL oxidation [7], 
vasorelaxation [8] and upregulation of NO synthase 
[9]. Free radical-scavenging activity was 
demonstrated in animal models with induced 
arrhythmia [10]. Obtained results showed 
prevention of induced arrhythmia and lower 
mortality due to anti-oxidant activity and ability of 
resveratrol to upregulate NO synthase [10]. In 
addition, it is well documented that resveratrol 
plays an important role in platelet aggregation 
generally by inhibition of arachidonic acid 
metabolizing enzymes and production of 
eicosanoids from human platelets, demonstrated by 
50% reduction of platelets in human plasma [11]. 
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Anticancer activity of resveratrol is related to 
modulation of activity of numerous genes and 
enzymes attributed with inhibition of 
carcinogenesis and induction of tumor cell death, 
such as downregulation of NF-κBsignaling 
pathways for example [12]. Another conducted in 
vitro and in vivo studies presented that resveratrol 
also has impact on COX2 and is responsible for 
downregulation of AKT and MAPK, associated 
with inflammation and tumorigenesis [13] [14] 
[15].  However, the main mechanism of anti-
proliferative effect of resveratrol has not been 
discovered yet in vivo due to unpredicted 
deregulation of multiple signaling pathways in 
tumor tissue [16], [17]. Despite the numerous 
advantages, resveratrol has extremely low aqueous 
solubility (0.05 mg/ml) [18], rapid degradation at 
physiological pH [19] and significant presystemic 
biotransformation mainly via glucuronide and 
sulfate conjugation [20].  Consequently, oral 
bioavailability of resveratrol is extremely low, 
almost zero, without possibility to achieve 
therapeutic concentration in target cells [21,22]. In 
order to optimize the unfavorable characteristics, a 
possible approach is incorporation in nanoparticles 
such as solid lipid nanoparticles, nanoemulsions 
and liposomes as promising platforms for delivery 
of resveratrol.   
 
II. LIPOSOMES AS PLATFORMS FOR 
DELIVERY OF RESVERATROL 
Liposomes are class of most promising 
platforms for delivery of hydrophobic drugs, first 
discovered in 1961 by Bangham [23]. Membranes 
of liposomes are composed of natural 
phospholipids or lipids approved by FDA. Most 
common lipids used for liposome formulation are 
egg phosphatidylcholine, soybean 
phosphatidylcholine, 1,2-distearolyl-sn-glycero-3-
phosphatydylcholine. Unique characteristics of 
liposomes are owing to the amphiphiliccharac-ter, 
low size and thickness of the membrane [24]. 
Liposomes are spherical in form, composed of 
phospholipid lamellas, which close central aqueous 
cavity suitable for encapsulation of hydrophobic 
and hydrophilic drugs.  
A recent study reported the potential of 
resveratrol as anticonvulsant agent incorporated in 
liposomes. For the purpose, Sprague-Dawley rats 
with penicillin induced epileptic seizures were 
tested. Results showed that resveratrol loaded 
liposomes can cross BBB, had immediate effect on 
epileptic seizures and significantly increased the 
activity of Glutathione S Transferase, 
Malondialdehyde and Superoxide dismutase 
compared with free solution of resveratrol [25].  
In another study, resveratrol was 
incorporated into chitosan-coated liposomes for 
treat-ment of vaginal infection. Resveratrol loaded 
liposomes showed sustained release and average 
size of 200 nm. Obtained results presented higher 
anti-inflammatory activity of resveratrol-loaded 
liposomes compared with free solution on LPS-
induced J774A.1 cells [26].   
Enhanced bioavailability of resveratrol 
was reported when combined with curcumin into 
liposomes in vivo. The concentration was tested in 
serum and prostate tissue and the results showed 
higher stability for longer period and significant 
anticancer effect on invasive adenocarcinoma [27].  
Cytotoxicity enhancement of resveratrol 
was also reported. Resveratrol was incorporated in 
liposomes modified with transferrin in order to 
direct the nanoparticle to target glioblastoma cells. 
Obtained results presented significantly higher 
cytotoxicity and internalization of resveratrol into 
glioblastoma cells, compared with free drug and 
non-modified liposomes which makes them 
promising candidates for resveratrol delivery [28].  
Bacteriostatic activity of resveratrol was 
evaluated using microdilution method. resveratrol 
loaded liposomes were prepared using thin film 
hydration method and the results revealed particle 
size of approximately 118 nm and high 
encapsulation efficiency. Obtained results showed 
that bacteriostatic activity of resveratrol loaded 
liposomes against Klebsiella pneumonia and 
methicillin-resistant Staphylococcus aureus is 
significantly higher with MIC from 70- 300 µg/ml 
compared with free solution of resveratrol. These 
results indicate that resveratrol loaded liposomes 
could be used as potential candidates for 
intrahospital infections [29].  
Confocal microscopy, flow cytometry and 
HPLC were used in order to determine the amount 
of resveratrol accumulation in cerebrovascular 
endothelial cells isolated from aged F344xBN rats. 
Resveratrol was encapsulated into novel fusogenic 
liposomes, composed of combination of positively 
charged lipid (1,2-dioleoyl-3-trimethylammonium-
propane, chloride salt DOTAP)  and conventional 
liposomes. Obtained results reported that the main 
mechanism of antioxidant effect of resveratrol is 
based on activation of cellular Nrf2 which 
significantly decreased the reactive oxygen species 
due to rapid delivery of the active substance by 
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In order to overcome the limitations of 
liposomes, in a recent study resveratrol was co-
encapsulated as liposomal formulation into 
cyclodextrine in form of inclusion complex. The 
obtained results showed complete drug release and 
high stability on room temperature for 4 days. 
Cytotoxicity was tested in vitro on colon cancer 
cell lines using MTS colorimetric assay and results 
showed significantly higher cytotoxicity of hybrid 
resveratrol nanoformulation compared with free 
DMSO solution of the active substance [31].  
Resveratrol loaded liposomes with 
enhanced bioavailability and stability were 
prepared by Balanc et al., for testing the 
antioxidant activity of the active agent. Liposomes 
were prepared by thin film hydration and 
proliposome method using commercial lipids 
DPPC and phopsholipon, characterized with 
spherical form, size of app.150 nm and negative 
zeta potential suitable for systemic application. 
Results showed 95% inhibition of lipid 
peroxidation compared with free solution [32]. 
Despite the numerous advantages listed 
above, low entrapment efficiency is the main 
problem associated with liposomes owing to the 
membrane destabilization because resveratrol is 
localized as hydrophobic molecule mainly into 
phospholipid bilayer. 
 
III. RESVERATROL LOADED 
NANOEMULSIONS 
Nanoemulsions are promising candidates 
for encapsulation and delivery of hydrophobic 
drugs due to low droplet size (20-200nm), high 
thermodynamic stability and low toxicity. Gen-
erally, nanoemulsions are composed of natural fats 
as lipid phase dispersed into aqueous phase with 
surfactants and natural emulsifiers used as 
stabilizers of the emulsion. Numerous research 
studies reported the potential of these nanocariers 
for delivery of resveratrol [33], [34].  
Resveratrol as a free powder encapsulated 
in self-nanoemulsifying delivery was tested as 
potential anti-fatigue agent in exhausted rats by 
measuring the parameters linked to this condition 
such as glucose, lactate and ammonia. 
Nanoemulsions were composed of Capryol 90, 
Cremophor EL, and Tween 20, and obtained 
nanoparticles were characterized with average size 
of 41 nm and negative zeta potential suitable for 
systemic application. Encapsulation into 
nanoemulsions not only showed improved oral 
bioavailability, but also decreased the plasma 
ammonia level, accelerated lactate recovery and 
increased the time of rats’ exhaustion by swimming 
[35]. 
An intriguing approach to overcome 
resveratrol pre-systemic and systemic transfor-
mation is incorporation in nanoemulsions prepared 
by emulsification method and high-pressure 
homogenization for treatment of Parkinson’s 
disease. As oil phase in nanoemulsion vitamin E 
and selfsol was used. Tween 80 and Transcutol P 
were used as surfactant and co-surfactant for 
stabilization of nanoemulsion. Results from this 
study showed size of 104 nm, negative zeta 
potential and high percentage of released 
resveratrol after 24 hours. Also, higher 
concentration of resveratrol in BBB was observed, 
associated with significantly lower concentration of 
MDA and higher level of GSH and SOD [36]. 
Nanoemulsions prepared by high-pressure 
homogenization method exhibited significant 
improvement in penetration of resveratrol in Caco 
2 cells compared to free drug in DMSO solution. 
Soy lecithin and Tween 20 were used as 
components in nanoemulsion. Also, increased 
physicochemical stability of the formulation in this 
study has been reported [37].  
However, the expensive formulation is 
one of the major disadvantages of nanoemulsions. 
Also, use of high concentration of surfactants and 
high environmental stability dependence 
significantly limits the application of 
nanoemulsions as platforms for drug delivery [38]. 
 
IV. CONCLUSION 
In summary, resveratrol was successfully 
incorporated into different nanoparticles such as 
liposomes, solid lipid nanoparticles and 
nanoemulsions described in this review. 
Resveratrol loaded nanoparticles showed 
remarkable advantages over non-encapsulated 
agent. Low-solubility problems, low systemic 
circulation and stability were significantly 
improved with encapsulation of this efficacious 
agent into nanoparticles.  However, despite the 
numerous ad-vantages of nanoparticles as 
platforms for resveratrol delivery, future in vitro 
and in vivo studies are required in order to achieve 
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